Full
Outline
To explore the dilemmas faced by primary healthcare institutions in China in the practice of cardiovascular metabolic disease management and to propose systematic directions for optimization.
A qualitative research approach was adopted.Semi-structured in-depth interviews were conducted with 13 frontline healthcare professionals involved in chronic disease management across nine primary healthcare institutions in four cities representing eastern,central,and western China.Thematic analysis was used to code the interview data and extract key themes.
Current cardiovascular metabolic disease management at the primary level faced seven major challenges:1)low patient adherence,frequent loss to follow-up,and inadequate management of high-risk populations and complications;2)insufficient human resources and excessive workload for medical staff;3)drug supply significantly affected by policies such as volume-based procurement,alongside a shortage of specialized diagnostic equipment;4)poor referral coordination between primary and higher-level institutions,with barriers to information sharing;5)inadequate multidisciplinary collaboration mechanisms and significant regional disparities in the composition of family doctor teams;6)low community participation in health education and limited coverage of early screening programs;and 7)fragmented information systems characterized by overlapping functions and insufficient stability.Additionally,the study summarized specific recommendations from respondents regarding workforce expansion,investment in prevention,expert support,and innovation in management models.
Chronic disease management in primary healthcare in China is undergoing a critical transition from "establishing presence" to "achieving excellence". To enhance quality and efficiency,systematic improvements are recommended in areas such as optimizing human resource allocation and incentive mechanisms, promoting information system integration and the application of artificial intelligence technologies,implementing targeted financial investment and resource allocation policies.
37
16
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
